Publication list
2023
2022
Lakatos, V.,
Herczku, A.,
Mikala, G.,
Lovas, S.,
Váróczy, L.,
Alizadeh, H.,
Ónodi, Á.,
Modok, S.:
Lenalidomide maintenance after autologous hematopoetic stem cell transplantation in Hungary from 2016 to 2021.
Clinical Lymphoma Myeloma and Leukemia. 22 S53, 2022.
Lovas, S.,
Obajed Al-Ali, N.,
Varga, G.,
Szita, V.,
Alizadeh, H.,
Plander, M.,
Rajnics, P.,
Illés, Á.,
Szemlaky, Z.,
Mikala, G.,
Váróczy, L.:
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients: Real-World Data From Hungary.
Pathol. Oncol. Res. 28 1-7, 2022.
Journal metrics:
Q3 Cancer Research
Q2 Medicine (miscellaneous)
Q3 Oncology
Q2 Pathology and Forensic Medicine
2021
Varga, G.,
Tóth, A.,
Virág, R.,
Csukly, Z.,
Hardi, A.,
Gaál-Weisinger, J.,
Nagy, Z.,
Altai, E.,
Rencsik, A.,
Plander, M.,
Szendrei, T.,
Kórád, K.,
Radványi, G.,
Rottek, J.,
Deák, B.,
Szaleczky, E.,
Schneider, T.,
Kohl, Z.,
Kosztolányi, S.,
Alizadeh, H.,
Lengyel, Z.,
Modok, S.,
Borbényi, Z.,
Lovas, S.,
Váróczy, L.,
Illés, Á.,
Rajnics, P.,
Masszi, T.,
Mikala, G.:
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: results of Real-Life Data From 11 Hungarian Centers.
Pathol. Oncol. Res. 27 1-6, 2021.
Journal metrics:
Q3 Cancer Research
Q2 Medicine (miscellaneous)
Q3 Oncology
Q2 Pathology and Forensic Medicine
2019
Szántó, K.,
Szíjártó, A.,
Kata, D.,
Földesi, I.,
Mezei, Z.,
Fábián, Á.,
Bálint, A.,
Bor, R.,
Farkas, K.,
Milassin, Á.,
Rutka, M.,
Szepes, Z.,
Nagy, F.,
Bubán, T.,
Lovas, S.,
Palatka, K.,
Molnár, T.:
Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre.
J. Crohns Colitis. 13 (Supplement1), S456, 2019.
Lovas, S.,
Varga, G.,
Farkas, P.,
Masszi, T.,
Wohner, N.,
Bereczki, Á.,
Adamkovich, N.,
Borbényi, Z.,
Szomor, Á.,
Alizadeh, H.,
Szaleczky, E.,
Wolf, K.,
Schneider, T.,
Plander, M.,
Szendrei, T.,
Csacsovszki, O.,
Csukly, Z.,
Rajnics, P.,
Egyed, M.,
Nagy, Z.,
Rejtő, L.,
Illés, Á.,
Mikala, G.,
Váróczy, L.:
Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients.
Int. J. Hematol. 110 (5), 559-565, 2019.
2018
Bálint, A.,
Rutka, M.,
Kolar, M.,
Bortlik, M.,
Duricova, D.,
Hruba, V.,
Lukas, M.,
Mitrova, K.,
Malickova, K.,
Lukas, M.,
Szepes, Z.,
Nagy, F.,
Palatka, K.,
Lovas, S.,
Végh, Z.,
Kürti, Z.,
Csontos, Á.,
Miheller, P.,
Nyári, T.,
Bor, R.,
Milassin, Á.,
Fábián, A.,
Szántó, K.,
Lakatos, P.,
Molnár, T.,
Farkas, K.:
Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis: results from multicenter observational cohort.
Expert Opin. Biol. Ther. 18 (11), 1181-1187, 2018.
Journal metrics:
Q1 Clinical Biochemistry
Q1 Drug Discovery
Q1 Pharmacology
Palatka, K.,
Kacska, S.,
Lovas, S.,
Garai, I.,
Varga, J.,
Galuska, L.:
The potential role of FDG PET-CT in the characterization of the activity of Crohn's disease, staging follow-up and prognosis estimation: a pilot study.
Scand. J. Gastroenterol. 53 (1), 24-30, 2018.
Rencz, F.,
Lakatos, P.,
Gulácsi, L.,
Brodszky, V.,
Kürti, Z.,
Lovas, S.,
Banai, J.,
Herszényi, L.,
Cserni, T.,
Molnár, T.,
Péntek, M.,
Palatka, K.:
Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.
Qual. Life Res. 28 (1), 141-152, 2018.
Journal metrics:
Q1 Public Health, Environmental and Occupational Health
2014
Galuska, L.,
Kis, S.,
Fedinecz, N.,
Palatka, K.,
Lovas, S.,
Garai, I.,
Varga, J.:
The value of FDG PET-CT in Crohn's disease to assess the prognosis of planned biological therapy (P819).
Eur. J. Nucl. Med. Mol. Imaging. 41 (S2), S593, 2014.
2013
Galuska, L.,
Kis, S.,
Fedinecz, N.,
Palatka, K.,
Lovas, S.,
Garai, I.,
Varga, J.:
Assessment of crohn's disease activity by FDG PET-CT (024).
Nucl. Med. Rev. Cent. E. Eur. 16 (Suppl.), A12, 2013.
Galuska, L.,
Kis, S.,
Fedinecz, N.,
Palatka, K.,
Lovas, S.,
Garai, I.,
Varga, J.:
Assessment of Crohn's disease activity by FDG PET-CT and Tc-99m HmPAO labeled white blood cell SPECT-CT in a prospective study (OP116).
Eur. J. Nucl. Med. Mol. Imaging. 40 (Supplement), S124-S125, 2013.
updated: 2024-04-21, 01:30
